Silverback Therapeutics I... (SBTX)

NASDAQ: SBTX · Real-Time Price · USD

5.87

0.06 (1.03%)

At close: Nov 09, 2022, 5:00 AM

Company Description

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases.

The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Silverback Therapeutics Inc.

Country	United States
IPO Date	Dec 3, 2020
Industry	Biotechnology
Sector	Healthcare
Employees	90
CEO	Dr. Peter A. Thompson M.D.

Contact Details

Address: 500 Fairview Avenue North Seattle, Washington United States
Website	https://www.silverbacktx.com

Stock Details

Ticker Symbol	SBTX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001671858
CUSIP Number	82835W108
ISIN Number	US82835W1080
Employer ID	81-1489190
SIC Code	2834

Key Executives

Name	Position
Jeffrey C. Pepe J.D., Ph.D.	Interim Chief Executive Officer, Gen. Counsel & Corporation Sec.
Russ Hawkinson	Senior Vice President of Fin., Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Dario Gobunquin CPA	Senior Director of Accounting & Controller
Dr. Peter A. Thompson FACP, M.D.	Co-Founder & Chairman of Directors
Jen More	Director of HR
Miguel Arcinas M.B.A.	Vice President of Corporation Devel. & Investor Relations
Sue Hamke	Senior Vice President of Clinical Operations

Latest SEC Filings

Date	Type	Title
Apr 08, 2025	4	Filing
Mar 24, 2025	SCHEDULE 13D/A	[Amend] Filing
Mar 21, 2025	4	Filing
Mar 20, 2025	S-8	Filing
Mar 20, 2025	10-K	Annual Report
Mar 20, 2025	8-K	Current Report
Mar 07, 2025	4	Filing
Mar 05, 2025	8-K	Current Report
Feb 04, 2025	4	Filing
Jan 31, 2025	S-3ASR	Automatic shelf registration statement of securiti...

View All SEC Filings